GE Healthcare to acquire Xcellerex
GE Healthcare, a unit of GE has signed an agreement to acquire Xcellerex, a provider of manufacturing technologies for the biopharmaceutical industry.
The acquisition of Xcellerex will allow GE Healthcare to expand its offering of products and services for the manufacture of biopharmaceuticals such as recombinant proteins, antibodies and vaccines.
Xcellerex develops and produces biomanufacturing systems and production-scale bioreactors based around single-use components which are complementary to GE Healthcare's products and range of media for cell culture.
Integrating the expertise and capabilities of the two companies will enable GE Healthcare to provide a range of added-value, integrated products and services to the biopharmaceutical industry.
GE Healthcare Life Sciences chief technology officer Nigel Darby said by adding Xcellerex's innovative products to the company's portfolio, it will be able to enhance customer offering.
"GE and Xcellerex share the vision that an integrated approach, where we can help customers optimize every stage of their manufacturing process, has the potential to increase production flexibility and to deliver higher yields of finished product while reducing time to market," Darby added.
Subject to customary closing conditions, the deal is anticipated to close in Q2, 2012.